Table 2 Distribution of post-operative outcomes in the treatment groups
Mictalase group (n = 56) | Control group (n = 55) | p value | |
|---|---|---|---|
15th postoperative day follow-up | |||
IPSS | 12 (6–16) | 10 (7–15) | 0.7 |
QoL | 2 (1–4) | 2 (1–3) | 0.1 |
Urine pH | 6.5 (5.5–6.5) | 5.5 (5.5–6.5) | 0.4 |
WBC-sediment (counts/HPF) | 90 (30–250) | 55 (30–134) | 0.4 |
RBC-sediment (counts/HPF) | 90 (39–450) | 66 (15–431) | 0.5 |
Urine specific gravity | 1013 (1008–1018) | 1015 (1011–1020) | 0.3 |
Positive urine culture | 3 (2.7) | 10 (9.0) | 0.04 |
30th postoperative day follow-up | |||
IPSS | 6 (3–11) | 10 (5–13) | 0.02 |
QoL | 2 (1–3) | 2 (1–4) | 0.1 |
Urine pH | 5.5 (5.5–7.0) | 5.5 (5.0–6.0) | 0.2 |
WBC-sediment (counts/HPF) | 70 (11–138) | 36 (25–81) | 0.8 |
RBC-sediment (counts/HPF) | 16 (7–65) | 20 (8–113) | 0.4 |
Urine specific gravity | 1015 (1015–1019) | 1014 (1010–1021) | 0.9 |
Positive urine culture | 1 (0.9) | 1 (0.9) | 1 |
Qmax, ml/s | 22.1 (19.0–28.2) | 22.8 (16.4–25.2) | 0.4 |
PVR, ml | 0 (0–0) | 0 (0–0) | 0.6 |